First-Line Tagraxofusp in BPDCN: Subgroup Analyses by Age and Fitness

Naveen Pemmaraju, MD, reviews subgroup analyses of tagraxofusp as first-line therapy in BPDCN, highlighting durable responses and successful transplant bridging across age and fitness groups

The program was sponsored by Menarini Stemline. The content was independently created by OncLive

Related Content:

Rapid Readouts
MonarchE: Primary Overall Survival Results Of Adjuvant Abemaciclib Plus Endocrine Therapy For HR+, HER2-, High-Risk Early Breast Cancer
Darovasertib Plus Crizotinib in First-Line Metastatic Uveal Melanoma: Phase 1/2 OptimUM-01 Results
First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial